Survival of patients with advanced hepatocellular carcinoma: Sorafenib versus other treatments

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 11, 2011, Pages 1612-1618

  Kim, Hwi Young ^a   Park, Joong Won ^a   Nam, Byung Ho ^a   Kim, Hyun Keun ^a   Choi, Joon Il ^a   Kim, Tae Hyun ^a   Kim, Hyun Beom ^a   Kim, Chang Min ^a  

^a National Cancer Center   (South Korea)

Author keywords

Hepatocellular carcinoma; Sorafenib; Survival; Therapeutics

Indexed keywords

ALPHA FETOPROTEIN; CAPECITABINE; CISPLATIN; DOXORUBICIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPARATIVE STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 80054908052     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06751.x     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E etal. Cancer statistics, 2008. CA Cancer J. Clin. 2008; 58: 71-96.
2. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.
3. Park KW, Park JW, Choi JI etal. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J. Gastroenterol. Hepatol. 2008; 23: 467-73.
4. NCCN. Clinical Practice Guidlines in Oncology: Hepatobiliary Cancers 2008. Cited 31 Oct 2007. Available from URL.
5. Llovet JM, Real MI, Montana X etal. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
6. Lo CM, Ngan H, Tso WK etal. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
8. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-90.
9. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
10. Llovet JM, Di Bisceglie AM, Bruix J etal. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl. Cancer Inst. 2008; 100: 698-711.
11. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 2008; 48 (Suppl. 1): S20-37.
12. Poon D, Anderson BO, Chen LT etal. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009; 10: 1111-18.
13. KLCSG-NCC. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J. Hepatol. 2009; 15: 391-423.
14. NCCN. Clinical Practice Guidlines in Oncology: Hepatobiliary Cancers 2009. Cited 9 Mar 2009. Available from URL.
15. Arii S, Sata M, Sakamoto M etal. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol. Res. 2010; 40: 667-85.
16. Kudo M. Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology 2010; 78 (Suppl. 1): 180-8.
17. Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am. J. Roentgenol. 1995; 165: 315-21.
18. Kim DY, Park W, Lim DH etal. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005; 103: 2419-26.
19. Yamada K, Izaki K, Sugimoto K etal. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57: 113-19.
20. Shim JH, Park JW, Nam BH, Lee WJ, Kim CM. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2009; 63: 459-67.
21. Park JW. [Practice guideline for diagnosis and treatment of hepatocellular carcinoma]. Korean J. Hepatol. 2004; 10: 88-98.
22. Finn RS. Drug therapy: sorafenib. Hepatology 2010; 51: 1843-9.
23. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 2010; 30: 61-74.
24. Shim JH, Park JW, Choi JI, Park BJ, Kim CM. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virus-endemic area. J. Cancer Res. Clin. Oncol. 2009; 135: 617-25.
25. Park JW, Park KW, Cho SH etal. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am. J. Gastroenterol. 2005; 100: 2194-200.
26. Kim TH, Kim DY, Park JW etal. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2007; 67: 225-31.
27. Thomas MB, Jaffe D, Choti MM etal. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J. Clin. Oncol. 2010; 28: 3994-4005.
28. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
29. Kim KM, Kim JH, Park IS etal. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J. Gastroenterol. Hepatol. 2009; 24: 806-14.